Search Results for 'abbreviations cont'
abbreviations cont published presentations and documents on DocSlides.
New Perspectives in Treatment Strategies for Follicular Lymphoma
by olivia-moreira
Introduction. Standard Frontline Therapy for FL. ...
Evidence-Based Antiplatelet Therapy Across the ACS Spectrum
by debby-jeon
Evidence-Based Antiplatelet Therapy Across the AC...
Novel Agents in Multiple Myeloma
by marina-yarberry
The Pharmacist's View on Therapy . Learning Objec...
Warfarin Important Drug-Drug Interactions With NOACs
by trish-goza
Comparative Pharmacology. Factors Related to Adhe...
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
by debby-jeon
Please note this program will include a discussio...
Can Omega-3s Reduce Cardiovascular Risk?
by briana-ranney
Focusing on Triglycerides. Primary and Secondary ...
Application of the Data:
by giovanna-bartolotta
Cardiometabolic Disease Is an Epidemic. Clinical ...
Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies
by cheryl-pisano
Learning Goals. Immunotherapies in B-Cell Maligna...
Atrial Fibrillation Long-Term Outcomes in Patients With AF
by alida-meadow
ICH in Asians. Causes of Death in Patients With A...
Monitoring and Modifying Treatment in PAH
by briana-ranney
Suggested Baseline and Serial Assessment of Patie...
Essential Updates in Atopic Dermatitis:
by aaron
Pathogenesis and the Future of AD Treatment. Epid...
Upfront Combination Therapy vs Step-Up Approach for PAH:
by phoebe-click
Program Themes. Case 1. Case 1: Background and Di...
Personalized Therapy in Relapsed or Refractory CLL
by kittie-lecroy
IWCLL Criteria for Treating CLL. Other Considerat...
Hiding in Plain Sight: How Cancer Evades the Immune System
by stefany-barnette
Cancer Immunoediting . Eliminationâž› Equilibrium...
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
by lindy-dunigan
Program Goals. Defining Multiple Myeloma. Case 1....
Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer
by pamella-moone
This program will include a discussion of . off-l...
Updates in Lymphoma From Recent Congresses
by lindy-dunigan
Therapeutic Targets in CLL. Venetoclax in Patient...
Dispelling Myths and Misconceptions
by phoebe-click
ACC/AHA 2013 Digoxin Guidelines for Heart Failure...
Discussion Outline Cells of the Immune System
by lois-ondreau
Innate Immunity. Receptors on T and B Cells Are S...
What Has Been Tried and What Is True?
by celsa-spraggs
What Has Changed?. Less Stent Thrombosis . With. ...
Appropriate Use Criteria for the Risk Assessment of Stable Ischemic Heart Disease
by trish-goza
Spectrum of Ischemic Heart Disease. Management of...
Optimizing Use of Biological Agents in Crohn Disease
by tatiana-dople
Introduction. Case 1: When to Start a Biologic?. ...
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients
by tawny-fly
Program Goals. The . Incretin System: Response to...
Ablation and Anticoagulation
by marina-yarberry
Risks of AF Ablation Procedure. Many Moving Parts...
PARP Inhibitors and Cancer: What Do You Need to Know?
by pasty-toler
This program will include a discussion of off-lab...
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice
by natalia-silvester
Pemphigus Vulgaris. Introduction. M. onitoring Tr...
Oral Antiplatelet Therapy in ACS
by kittie-lecroy
Oral Antiplatelet Therapy in ACS PLATO Primary E...
Post-autologous Transplant Therapy for Hodgkin Lymphoma
by sherrill-nordquist
Program Goals. cHL. Overview. cHL. Poor Prognosis...
Updates in Diffuse Large B-Cell Lymphoma
by sherrill-nordquist
Program Goals. DLBCL Subtypes . 2008 WHO Classifi...
Atypical HUS: Improving Patient Care From Diagnosis to Treatment
by phoebe-click
Program Goal. TMA Diseases. Classification of HUS...
Giant Cell Arteritis Judy's Symptoms
by danika-pritchard
Judy's Symptoms (cont). GCA. Headache. Cranial Sy...
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer
by trish-goza
1899: Coley’s Toxin. 2016: PD-1 Inhibition. 201...
What You Didn't Know About AF and Renal Dysfunction
by lois-ondreau
Percentage of Strokes Attributable to AF Increase...
Clinical Considerations in the Management of Metastatic Col
by danika-pritchard
Disease Progression. Program Goals. Introduction....
The Biology of Relapsed and Refractory Multiple Myeloma
by alexa-scheidler
Topics. Current Treatment Options for Relapsed/Re...